Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:55:09 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



Q:HEPA - HEPION PHARMACEUTICALS INC - https://hepionpharma.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
HEPA - Q0.41.38·1.510.12.01+0.021.0154.52263562.13  2.20  2.0120.66  1.4919:50:2116:3015 min RT 2¢

Recent Trades - Last 10 of 356
Time ETExPriceChangeVolume
19:50:21Q1.38-0.731850
19:50:08Q1.38-0.7318400
19:42:40Q1.40-0.7118555
19:35:35Q1.40-0.7118114
19:34:29Q1.3998-0.71270
19:33:29Q1.37-0.741813
19:24:45Q1.36-0.7518250
19:05:21Q1.40-0.7118141
18:57:04Q1.35-0.76181,000
18:56:52Q1.35-0.76185,000

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-19 16:30U:HEPANews ReleaseHepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' Trial
2024-03-06 08:30U:HEPANews ReleaseHepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell
2024-02-16 08:00U:HEPANews ReleaseHepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds
2024-01-03 17:15U:HEPANews ReleaseHepion Pharmaceuticals to Present at NASH-TAG 2024
2023-12-07 08:00U:HEPANews ReleaseHepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes
2023-11-28 16:15U:HEPANews ReleaseHepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit
2023-11-13 16:05U:HEPANews ReleaseHepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease
2023-11-10 08:50U:HEPANews ReleaseHepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ¢ € ˜ALTITUDE-NASH ¢ € ™ Liver Function Trial of Rencofilstat
2023-10-25 08:30U:HEPANews ReleaseHepion Pharmaceuticals ¢ € ™ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model
2023-09-29 08:00U:HEPANews ReleaseHepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
2023-09-21 16:05U:HEPANews ReleaseHepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference
2023-09-21 08:00U:HEPANews ReleaseNew Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals ¢ € ™ Rencofilstat in Cancer Screening Program
2023-09-19 09:00U:HEPANews ReleaseHepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancer
2023-09-14 08:45U:HEPANews ReleaseRencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary Fibrosis
2023-09-06 16:30U:HEPANews ReleaseHepion Pharmaceuticals Announces Management Changes
2023-06-15 16:45U:HEPANews ReleaseHepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress ¢ „ ¢ 2023
2023-06-15 08:22U:HEPANews ReleaseHepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ¢ € ˜ASCEND-NASH ¢ € ™ Trial of Rencofilstat
2023-05-24 16:45U:HEPANews ReleaseHepion Pharmaceuticals to Highlight AI-POWR ¢ „ ¢ at the 2023 CSPS Annual Symposium: The Next Frontiers in Pharmaceutical Sciences
2023-05-22 07:00U:HEPANews ReleaseHepion Pharmaceuticals ¢ € ™ Phase 2 ¢ € ˜ALTITUDE-NASH ¢ € ™ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers
2023-05-19 16:05U:HEPANews ReleaseHepion Pharmaceuticals Schedules Conference Call to Review Topline Results from Phase 2 ¢ € ˜ALTITUDE-NASH ¢ € ™ Liver Function Trial of Rencofilstat